These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9058732)

  • 1. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells.
    Kaufmann SH; Svingen PA; Gore SD; Armstrong DK; Cheng YC; Rowinsky EK
    Blood; 1997 Mar; 89(6):2098-104. PubMed ID: 9058732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia.
    Rowinsky EK; Adjei A; Donehower RC; Gore SD; Jones RJ; Burke PJ; Cheng YC; Grochow LB; Kaufmann SH
    J Clin Oncol; 1994 Oct; 12(10):2193-203. PubMed ID: 7931489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
    Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
    Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I and pharmacological study of topotecan infused over 30 minutes for five days in patients with refractory acute leukemia.
    Rowinsky EK; Kaufmann SH; Baker SD; Miller CB; Sartorius SE; Bowling MK; Chen TL; Donehower RC; Gore SD
    Clin Cancer Res; 1996 Dec; 2(12):1921-30. PubMed ID: 9816150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantification of topoisomerase-DNA complexes in leukemia cells from patients undergoing therapy with a topoisomerase-directed agent.
    Ellis AL; Nowak B; Plunkett W; Zwelling LA
    Cancer Chemother Pharmacol; 1994; 34(3):249-56. PubMed ID: 8004759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal encapsulation increases the activity of the topoisomerase I inhibitor topotecan.
    Subramanian D; Muller MT
    Oncol Res; 1995; 7(9):461-9. PubMed ID: 8835290
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The current status of camptothecin analogues as antitumor agents.
    Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
    J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
    Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
    Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia.
    Kantarjian HM; Beran M; Ellis A; Zwelling L; O'Brien S; Cazenave L; Koller C; Rios MB; Plunkett W; Keating MJ
    Blood; 1993 Mar; 81(5):1146-51. PubMed ID: 8382970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
    Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
    Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
    Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
    Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro.
    Ma J; Maliepaard M; Nooter K; Boersma AW; Verweij J; Stoter G; Schellens JH
    Cancer Chemother Pharmacol; 1998; 41(4):307-16. PubMed ID: 9488600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of topoisomerase I inhibition: Western blot determination of topoisomerase I and cleavable complex in patients with upper gastrointestinal malignancies treated with topotecan.
    Liebes L; Potmesil M; Kim T; Pease D; Buckley M; Fry D; Cho J; Adler H; Dar K; Zeleniuch-Jacquotte A; Hochster H
    Clin Cancer Res; 1998 Mar; 4(3):545-57. PubMed ID: 9533521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. RNA synthesis inhibitors alter the subnuclear distribution of DNA topoisomerase I.
    Buckwalter CA; Lin AH; Tanizawa A; Pommier YG; Cheng YC; Kaufmann SH
    Cancer Res; 1996 Apr; 56(7):1674-81. PubMed ID: 8603419
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human DNA topoisomerase I: quantitative analysis of the effects of camptothecin analogs and the benzophenanthridine alkaloids nitidine and 6-ethoxydihydronitidine on DNA topoisomerase I-induced DNA strand breakage.
    Holden JA; Wall ME; Wani MC; Manikumar G
    Arch Biochem Biophys; 1999 Oct; 370(1):66-76. PubMed ID: 10496978
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
    Lamond JP; Wang M; Kinsella TJ; Boothman DA
    Int J Radiat Oncol Biol Phys; 1996 Sep; 36(2):361-8. PubMed ID: 8892461
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of novel human leukemic cell lines selected for resistance to merbarone, a catalytic inhibitor of DNA topoisomerase II.
    Kusumoto H; Rodgers QE; Boege F; Raimondi SC; Beck WT
    Cancer Res; 1996 Jun; 56(11):2573-83. PubMed ID: 8653700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia.
    Gore SD; Rowinsky EK; Miller CB; Griffin C; Chen TL; Borowitz M; Donehower RC; Burks KL; Armstrong DK; Burke PJ; Grever MR; Kaufmann SH
    Clin Cancer Res; 1998 Nov; 4(11):2677-89. PubMed ID: 9829730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
    Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.